{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:55:48Z","timestamp":1777712148869,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Lower Extremity Wounds"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>New antimicrobial agents have been developed to treat infections caused by methicillin-resistant Staphylococcus aureus and other multidrug-resistant pathogens. Dalbavancin is a novel semisynthetic lipoglycopeptide antibiotic, particularly active against methicillin-resistant Staphylococcus aureus. Due to its unique pharmacological characteristics and longer half-life, it can be administered once-weekly or every 15 days and in outpatient setting. Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.<\/jats:p>","DOI":"10.1177\/1534734620921677","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T08:11:06Z","timestamp":1591344666000},"page":"236-241","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections"],"prefix":"10.1177","volume":"19","author":[{"given":"Vasilios","family":"Petrakis","sequence":"first","affiliation":[{"name":"University Hospital of Alexandroupolis, Alexandroupolis, Greece"},{"name":"Democritus University of Thrace, Alexandroupolis, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[{"name":"University Hospital of Alexandroupolis, Alexandroupolis, Greece"},{"name":"Democritus University of Thrace, Alexandroupolis, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[{"name":"University Hospital of Alexandroupolis, Alexandroupolis, Greece"},{"name":"Democritus University of Thrace, Alexandroupolis, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"bibr1-1534734620921677","unstructured":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. http:\/\/www.fda.gov\/downloads\/Drugs\/.\/Guidances\/ucm071185.pdf. Published October 2013. Accessed April 17, 2020."},{"key":"bibr2-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu444"},{"key":"bibr3-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw255"},{"key":"bibr4-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.12.004"},{"key":"bibr5-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1071-0"},{"key":"bibr6-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.14.1585"},{"key":"bibr7-1534734620921677","unstructured":"European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011-2012. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/healthcare-associated-infections-antimicrobial-use-PPS.pdf. Published July 4, 2013. Accessed April 17, 2020."},{"key":"bibr8-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.04.023"},{"key":"bibr9-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.03.016"},{"key":"bibr10-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12235"},{"key":"bibr11-1534734620921677","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2018. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/surveillance-antimicrobial-resistance-Europe-2018.pdf. Published 2018. Accessed April 17, 2020."},{"key":"bibr12-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00551-07"},{"key":"bibr13-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000353"},{"key":"bibr14-1534734620921677","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"bibr15-1534734620921677","unstructured":"Dalvance\u2122 [package insert]. Chicago, IL: Durata Therapeutics; 2014."},{"key":"bibr16-1534734620921677","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S86330"},{"key":"bibr17-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz162"},{"key":"bibr18-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0156-z"},{"key":"bibr19-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2057"},{"key":"bibr20-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(03)00120-0"},{"key":"bibr21-1534734620921677","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070255"},{"key":"bibr22-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.605"},{"key":"bibr23-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2344-2348.2002"},{"key":"bibr24-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki005"},{"key":"bibr25-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01318.x"},{"key":"bibr26-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008330162"},{"key":"bibr27-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04550-14"},{"key":"bibr28-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/S0213-005X(17)30031-9"},{"key":"bibr29-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005280378"},{"key":"bibr30-1534734620921677","first-page":"291","volume":"9","author":"Stogniew M","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"bibr31-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl311"},{"key":"bibr32-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.770-772.2005"},{"key":"bibr33-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"bibr34-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki007"},{"key":"bibr35-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.05.014"},{"key":"bibr36-1534734620921677","unstructured":"FDA Briefing Document Anti-infective Advisory Committee Meeting\u2014NDA 21883: Dalvance (Dalbavancin) for injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/021883Orig1s000SumR.pdf. Published March 31, 2014. Accessed April 17, 2020."},{"key":"bibr37-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1968-1971.2003"},{"key":"bibr38-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.12.015"},{"key":"bibr39-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.11.007"},{"key":"bibr40-1534734620921677","unstructured":"Xydalba. Annex I. Summary of product characteristics. Community register 2015. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150219130765\/anx_130765_en.pdf. Accessed April 17, 2020."},{"key":"bibr41-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310480"},{"key":"bibr42-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0374-9"},{"key":"bibr43-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"bibr44-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ982"},{"key":"bibr45-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.481251"},{"key":"bibr46-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.08.028"},{"key":"bibr47-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.008"},{"key":"bibr48-1534734620921677","first-page":"225","volume":"12","author":"Juul JJ","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"bibr49-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2014.12.001"},{"key":"bibr50-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.02.013"},{"key":"bibr51-1534734620921677","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"Rappo U","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"bibr52-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.10.007"},{"key":"bibr53-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02280-18"},{"key":"bibr54-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00286-06"},{"key":"bibr55-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-019-01354-x"},{"key":"bibr56-1534734620921677","first-page":"532","volume":"32","author":"Mart\u00edn LB","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"bibr57-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040181"},{"key":"bibr58-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2845-z"},{"key":"bibr59-1534734620921677","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.09.015"}],"container-title":["The International Journal of Lower Extremity Wounds"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534734620921677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1534734620921677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534734620921677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:04:23Z","timestamp":1777457063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1534734620921677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/1534734620921677"],"URL":"https:\/\/doi.org\/10.1177\/1534734620921677","relation":{},"ISSN":["1534-7346","1552-6941"],"issn-type":[{"value":"1534-7346","type":"print"},{"value":"1552-6941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}